<DOC>
	<DOCNO>NCT00382928</DOCNO>
	<brief_summary>We propose randomize automatic external cardioverter/defibrillators ( AECD ) patient high risk life-threatening abnormal heart rhythm ( arrhythmia ) admit telemetry ward , treatment constant include cardiopulmonary resuscitation . We hypothesize automatic , rapid , accurate specific diagnostic therapeutic technology use AECDs increase rate survival patient cardiac arrest rapid automatic defibrillation , independent operator initiation , compare standard cardiopulmonary resuscitation initiate healthcare provider .</brief_summary>
	<brief_title>Automatic External Defibrillation Monitoring Cardiac Arrest</brief_title>
	<detailed_description>Cardiac arrest ( CA ) define sudden cessation effective cardiac pump function result either ventricular asystole ( inactivity heart ) pulseless ventricular tachycardia/ventricular fibrillation ( VT/VF ) . Pulseless ventricular tachycardia/ventricular fibrillation abnormal electrical activity ventricle heart . Rapid diagnosis treatment essential first , minute total CA result permanent damage brain due lack oxygen , second , success resuscitative measure relate rapidity institute follow arrest . For person VT/VF probability successful defibrillation subsequent survival hospital discharge directly negatively related interval onset VT/VF delivery first shock . Comparison : By use AECDs evaluate automatic , rapid , accurate specific diagnostic technology increase rate survival patient VT/VF rapid automatic defibrillation , independent operator initiation , compare standard cardiopulmonary resuscitation ( CPR ) conventional defibrillator initiate healthcare provider . This trial randomize , control trial test AECDs improve outcome measure compare traditional response . Conventional defibrillator manually operate defibrillator attach patient operate healthcare provider layperson . In contrast , purpose AECDs automatically detect life-threatening arrhythmia deliver external shock accord programmable prescription hospitalize patient , may transient risk development life-threatening arrhythmia . AECDs immediately automatically monitor , detect treat cardiac arrhythmia human intervention . The AECD propose utilized trial , PowerHeart CRM , product Cardiac Science , Inc , evaluate hospital setting ass safety efficacy , approve FDA prophylactically attach hospital patient provide automatic defibrillation therapy without human intervention . All patient admit telemetry unit ask volunteer study . Up 3,000 patient ask volunteer study stay telemetry unit . This study evaluate way improve survival CA compare two group Group 1 : This group include patient admitted telemetry unit undergo standard measure CPR case cardiac arrest suspect . Group 2 : This group include patient admitted telemetry unit AECD attach chest wall also undergo standard measure CPR case cardiac arrest .</detailed_description>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<mesh_term>Death , Sudden</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>All patient admit telemetry ward emergency department Age &gt; 18 year . Pregnant woman Patients R wave less 0.5 millivolt . Patients function Internal Cardiac Device . Patients cardiac pacemaker oversensing AECD demonstrate ( double count pacer spike ) . Patients visible chest lesion would prevent AECD pad placement . Patients designate Do Not Resuscitate . Right bundle branch block . Patients Parkinson 's disease . Patients seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Defibrillators</keyword>
	<keyword>Medical Devices</keyword>
</DOC>